These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11786175)

  • 1. A review of the literature on the economics of noncompliance. Room for methodological improvement.
    Cleemput I; Kesteloot K; DeGeest S
    Health Policy; 2002 Jan; 59(1):65-94. PubMed ID: 11786175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.
    Muszbek N; Brixner D; Benedict A; Keskinaslan A; Khan ZM
    Int J Clin Pract; 2008 Feb; 62(2):338-51. PubMed ID: 18199282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic review of compliance with medication therapy in the treatment of schizophrenia.
    Thieda P; Beard S; Richter A; Kane J
    Psychiatr Serv; 2003 Apr; 54(4):508-16. PubMed ID: 12663838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluations and randomized trials in spinal disorders: principles and methods.
    Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L
    Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accounting for noncompliance in pharmacoeconomic evaluations.
    Hughes DA; Bagust A; Haycox A; Walley T
    Pharmacoeconomics; 2001; 19(12):1185-97. PubMed ID: 11772154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of relapse in schizophrenia.
    Weiden PJ; Olfson M
    Schizophr Bull; 1995; 21(3):419-29. PubMed ID: 7481573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of perceived barriers on compliance with antihypertensive medication.
    Richardson MA; Simons-Morton B; Annegers JF
    Health Educ Q; 1993; 20(4):489-503. PubMed ID: 8307768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the cost-effectiveness of interventions to improve seamless care focusing on medication.
    Simoens S; Spinewine A; Foulon V; Paulus D
    Int J Clin Pharm; 2011 Dec; 33(6):909-17. PubMed ID: 21979148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment.
    Khan MA; Walley JD; Witter SN; Imran A; Safdar N
    Health Policy Plan; 2002 Jun; 17(2):178-86. PubMed ID: 12000778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support.
    Wade AG; Häring J
    Int Clin Psychopharmacol; 2010 Sep; 25(5):288-96. PubMed ID: 20715299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic evaluation of health care.
    Haas M; Hall J
    Health Inf Manag; 1998 Dec-1999 Feb; 28(4):169-72. PubMed ID: 10387363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The measurement of indirect costs in the health economics evaluation literature. A review.
    Jacobs P; Fassbender K
    Int J Technol Assess Health Care; 1998; 14(4):799-808. PubMed ID: 9885468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication noncompliance: an issue to consider in the drug selection process.
    Feldman JA; DeTullio PL
    Hosp Formul; 1994 Mar; 29(3):204-11. PubMed ID: 10132693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of noncompliance in patients with schizophrenia.
    Perkins DO
    J Clin Psychiatry; 2002 Dec; 63(12):1121-8. PubMed ID: 12523871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data.
    Amato L; Fusco D; Acampora A; Bontempi K; Rosa AC; Colais P; Cruciani F; D'Ovidio M; Mataloni F; Minozzi S; Mitrova Z; Pinnarelli L; Saulle R; Soldati S; Sorge C; Vecchi S; Ventura M; Davoli M
    Epidemiol Prev; 2017; 41(5-6 (Suppl 2)):1-128. PubMed ID: 29205995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analyses in the health-care literature: don't judge a study by its label.
    Zarnke KB; Levine MA; O'Brien BJ
    J Clin Epidemiol; 1997 Jul; 50(7):813-22. PubMed ID: 9253393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.